ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2217

Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
Abstract Number: 0117

Disparities in Prescription Medications Among Myositis Patients in a Large Urban Medical Center
Abstract Number: 2106

Disparities of African American Mortality Trends in South Carolina Lupus Cohort
Abstract Number: 1565

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
Abstract Number: 1556

Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Abstract Number: 1054

Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema
Abstract Number: 0625

Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients
Abstract Number: 1171

Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Abstract Number: 1390

Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort
Abstract Number: 0016

Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE
Abstract Number: 1228

Distinctive Alterations in the Functional Anatomy of the Cerebral Cortex in Pain-sensitized Osteoarthritis and Fibromyalgia Patients
Abstract Number: 2029

Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
Abstract Number: 0687

DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients
Abstract Number: 2255

Do Fatty Lesions Explain the Association Between Inflammation and New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis?
Abstract Number: 1496

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].